Table 1 Baseline characteristics of patients infused with CAR T-cell therapy.
Characteristic | Patients with active EMD prior to infusion (N = 47) | Patients without EMD prior to infusion (N = 105) | p Value |
|---|---|---|---|
Median age (range) | 60 (43–78) | 65 (41–81) | 0.0125 |
Male gender, n (%) | 26 (55) | 56 (53) | 0.8615 |
Race/ethnicity, n (%) | |||
White | 39 (83) | 84 (80) | 0.8239 |
Black, Hispanic, or Other | 8 (17) | 21 (20) | |
ECOG PS, n (%) | |||
0–1 | 38 (81) | 94 (90) | 0.1931 |
2–3 | 9 (19) | 11 (10) | |
R-ISS stage, n (%) | |||
Stage I | 5/28 (18) | 10/69 (15) | 0.3621 |
Stage II | 11/28 (39) | 38/69 (55) | |
Stage III | 12/28 (43) | 21/69 (30) | |
High tumor marrow burden, n (%) | 9/44 (21) | 23/99 (23) | 0.7130 |
High risk cytogenetics, n (%) | 13/37 (35) | 36/83 (43) | 0.3965 |
deletion 17 | 7/37 (19) | 21/83 (25) | |
t (4;14) | 4/37 (11) | 12/83 (14) | |
t (14;16) | 3/37 (8) | 3/83 (4) | |
Plasma cell leukemia | 1 (2) | 7 (7) | 0.2468 |
Systemic bridging therapy, n (%) | 40 (85) | 87 (83) | 0.7296 |
Alkylator-based | 24 (51) | 34 (32) | |
Selinexor-based | 6 (13) | 17 (16) | |
PI-combos | 5 (11) | 16 (15) | |
IMiD-combos | 2 (4) | 12 (12) | |
Other | 3 (6) | 8 (8) | |
Radiation prior to CAR T | 17 (36) | 5 (5) | <0.0001 |
Median prior lines of therapy (range) | 6 (4–15) | 6 (4–15) | 0.5543 |
Prior autologous SCT, n (%) | 40 (85) | 77 (73) | 0.1111 |
Prior allogeneic SCT, n (%) | 2 (4) | 3 (3) | 0.6551 |
Refractory status, n (%) | |||
Triple refractory | 41 (87) | 88 (83) | 0.5861 |
Penta refractory | 19 (40) | 39 (37) | 0.7002 |
Prior anti-BCMA therapy, n (%) | 8 (17) | 17 (16) | 0.8984 |
Belantamab mafodotin | 4 (9) | 13 (12) | |
Teclistamab | 3 (6) | 0 | |
REGN5458 | 1 (2) | 1 (1) | |
SEA-BCMA | 0 | 2 (2) | |
Allogeneic CAR T | 0 | 1 (1) | |
Type of product, n (%) | |||
Idecabtagene vicleucel | 36 (77) | 72 (69) | 0.3134 |
Ciltacabtagene autoleucel | 11 (23) | 33 (31) | |
